Probiotics and Their Bioproducts: A Promising Approach for Targeting Methicillin-Resistant IStaphylococcus aureus/I and Vancomycin-Resistant IEnterococcus/I

• Published in: Microorganisms (Basel) 2023-09, Vol.11 (10)
• Main Authors: Jain, Manav, Stitt, Gideon, Son, Luke, Enioutina, Elena Y
• Format: Article
• Language: English
• Subjects: Biological products; Care and treatment; Drug resistance in microorganisms; Enterococcal infections; Health aspects; Medical research; Medicine, Experimental; Probiotics; Staphylococcus aureus infections
• ISSN: 2076-2607; 2076-2607
• DOI: 10.3390/microorganisms11102393

Antibiotic resistance is a serious global health problem that poses a threat to the successful treatment of various bacterial infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Conventional treatment of MRSA and VRE infections is challenging and often requires alternative or combination therapies that may have limited efficacy, higher costs, and/or more adverse effects. Therefore, there is an urgent need to find new strategies to combat antibiotic-resistant bacteria. Probiotics and antimicrobial peptides (AMPs) are two promising approaches that have shown potential benefits in various diseases. Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts. AMPs, usually produced with probiotic bacteria, are short amino acid sequences that have broad-spectrum activity against bacteria, fungi, viruses, and parasites. Both probiotics and AMPs can modulate the host immune system, inhibit the growth and adhesion of pathogens, disrupt biofilms, and enhance intestinal barrier function. In this paper, we review the current knowledge on the role of probiotics and AMPs in targeting multi-drug-resistant bacteria, with a focus on MRSA and VRE. In addition, we discuss future directions for the clinical use of probiotics.